HALO Halozyme Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HALO

Price (delayed)

$33.7

Market cap

$4.56B

P/E Ratio

22.77

Dividend/share

N/A

EPS

$1.48

Enterprise value

$5.83B

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in ...

Highlights
The company's revenue rose by 49% YoY and by 14% QoQ
HALO's gross profit is up by 44% YoY and by 13% QoQ
The company's equity has surged by 75% QoQ but it fell by 14% YoY
The debt has soared by 72% YoY
HALO's net income is down by 50% year-on-year and by 4.3% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.halozyme.com
Peers: MNKD LLY BAX PFE

Key stats

What are the main financial stats of HALO
Market
Shares outstanding
135.37M
Market cap
$4.56B
Enterprise value
$5.83B
Valuations
Price to earnings (P/E)
22.77
Price to book (P/B)
26.84
Price to sales (P/S)
6.99
EV/EBIT
21.94
EV/EBITDA
18.49
EV/Sales
8.84
Earnings
Revenue
$660.12M
EBIT
$265.87M
EBITDA
$315.51M
Free cash flow
$261.31M
Per share
EPS
$1.48
Free cash flow per share
$1.91
Book value per share
$1.26
Revenue per share
$4.82
TBVPS
$6.47
Balance sheet
Total assets
$1.84B
Total liabilities
$1.67B
Debt
$1.51B
Equity
$169.8M
Working capital
$608.22M
Liquidity
Debt to equity
8.87
Current ratio
5.65
Quick ratio
4.54
Net debt/EBITDA
4.03
Margins
EBITDA margin
47.8%
Gross margin
78.9%
Net margin
30.6%
Operating margin
40.5%
Efficiency
Return on assets
12.2%
Return on equity
98.6%
Return on invested capital
14.4%
Return on capital employed
15.5%
Return on sales
40.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HALO stock price

How has the Halozyme Therapeutics stock price performed over time
Intraday
2.56%
1 week
-6.57%
1 month
-33.07%
1 year
-10.32%
YTD
-40.77%
QTD
-40.77%

Financial performance

How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$660.12M
Gross profit
$520.81M
Operating income
$267.53M
Net income
$202.13M
Gross margin
78.9%
Net margin
30.6%
The net margin has plunged by 66% YoY and by 16% from the previous quarter
HALO's net income is down by 50% year-on-year and by 4.3% since the previous quarter
The company's revenue rose by 49% YoY and by 14% QoQ
HALO's gross profit is up by 44% YoY and by 13% QoQ

Growth

What is Halozyme Therapeutics's growth rate over time

Valuation

What is Halozyme Therapeutics stock price valuation
P/E
22.77
P/B
26.84
P/S
6.99
EV/EBIT
21.94
EV/EBITDA
18.49
EV/Sales
8.84
HALO's EPS is down by 48% year-on-year and by 2.6% since the previous quarter
The stock's price to earnings (P/E) is 6% less than its last 4 quarters average of 23.6
The company's equity has surged by 75% QoQ but it fell by 14% YoY
HALO's price to book (P/B) is 27% lower than its last 4 quarters average of 35.8 and 9% lower than its 5-year quarterly average of 28.9
The price to sales (P/S) is 49% lower than the 5-year quarterly average of 13.4 and 40% lower than the last 4 quarters average of 11.3
The company's revenue rose by 49% YoY and by 14% QoQ

Efficiency

How efficient is Halozyme Therapeutics business performance
Halozyme Therapeutics's return on assets has shrunk by 68% YoY and by 15% QoQ
The ROE has plunged by 59% YoY
HALO's return on sales is down by 30% year-on-year and by 5% since the previous quarter
HALO's return on invested capital is down by 19% year-on-year but it is up by 2.9% since the previous quarter

Dividends

What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HALO.

Financial health

How did Halozyme Therapeutics financials performed over time
The company's total assets is 10% higher than its total liabilities
The total liabilities has surged by 84% year-on-year but it has declined by 5% since the previous quarter
The company's total assets has surged by 67% YoY
Halozyme Therapeutics's debt to equity has soared by 99% YoY but it has decreased by 43% from the previous quarter
The company's equity has surged by 75% QoQ but it fell by 14% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.